![Elisabeth Leiderman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elisabeth Leiderman
Director/Board Member at
AUTOLUS THERAPEUTICS PLC
Net worth: - $ as of 31/05/2026
Profile
Elisabeth Leiderman is currently Non-Executive Director at Autolus Therapeutics Plc since 2023 and Chief Financial Officer at Dewpoint Therapeutics, Inc. starting in 2024.
Former roles include Independent Director at Genetix Biotherapeutics, Inc. from 2021 to 2025, Chief Financial & Business Officer at Atsena Therapeutics, Inc. from 2022 to 2023, Chief Financial & Accounting Officer at Decibel Therapeutics, Inc. from 2021 to 2022, Chief Business Officer at Complexa, Inc. from 2016 to 2020, Executive Director at Nomura Securities, Inc. from 2013 to 2016, and VP-Business & Corporate Development at Fortress Biotech, Inc. from 2007 to 2016.
Education includes undergraduate studies at the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from Sackler School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Elisabeth Leiderman active positions
| Companies | Position | Start |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 20/12/2023 |
Dewpoint Therapeutics, Inc.
 Dewpoint Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biomolecular condensates biotechnology company | Director of Finance/CFO | 01/06/2024 |
Former positions of Elisabeth Leiderman
| Companies | Position | End |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Director/Board Member | 02/06/2025 |
Atsena Therapeutics, Inc.
 Atsena Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage gene therapy company that develops treatments for inherited retinal diseases that cause blindness | Director of Finance/CFO | 01/11/2023 |
| DECIBEL THERAPEUTICS, INC. | Director of Finance/CFO | 07/10/2022 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Corporate Officer/Principal | 01/08/2020 |
Nomura Securities, Inc. | Director/Board Member | 01/07/2016 |
Training of Elisabeth Leiderman
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
39
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Fortress Biotech, Inc.
 Fortress Biotech, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical and biotechnology products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sackler School of Medicine
 Sackler School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Decibel Therapeutics, Inc.
 Decibel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines for hearing and balance disorders | Health Technology |
Autolus Therapeutics Plc
 Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biomolecular condensates biotechnology company | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage gene therapy company that develops treatments for inherited retinal diseases that cause blindness | Health Technology |
Nomura Securities, Inc. |
- Stock Market
- Insiders
- Elisabeth Leiderman
